obesity-995x60.png
FEATURED ARTICLES
What SIP Gets Right And Where It Still Falls Short
SIP users Sophie Haynes and Vicki Alvarez identify features that provide value but question whether the platform eliminates enough work to justify its setup demands, repetitive processes, and usability challenges.
-
Your Trial Shows Up In AI. Now What?
AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
-
The Promise Of MRD-Guided CAR-T Treatment
Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials
Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.